Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug

Laurie S. Conklin, Jesse M. Damsker, Eric P. Hoffman, William J. Jusko, Panteleimon D. Mavroudis, Benjamin D. Schwartz, Laurel J. Mengle-Gaw, Edward C. Smith, Jean K. Mah, Michela Guglieri, Yoram Nevo, Nancy L Kuntz, Craig M. McDonald, Mar Tulinius, Monique M. Ryan, Richard Webster, Diana Castro, Richard S. Finkel, Andrea L. Smith, Lauren P. MorgenrothAdrienne Arrieta, Maya Shimony, Mark Jaros, Phil Shale, John M. McCall, Yetrib Hathout, Kanneboyina Nagaraju, John van den Anker, Leanne M. Ward, Alexandra Ahmet, Michaelyn R. Cornish, Paula R. Clemens*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

48 Scopus citations

Fingerprint

Dive into the research topics of 'Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug'. Together they form a unique fingerprint.

Medicine and Dentistry

Chemistry

Pharmacology, Toxicology and Pharmaceutical Science